2022
DOI: 10.1186/s13048-022-01020-1
|View full text |Cite
|
Sign up to set email alerts
|

Maintenance therapy for newly diagnosed epithelial ovarian cancer– a review

Abstract: Epithelial ovarian cancer (EOC) is the most lethal gynaecological cancer among women worldwide, with the 5-year survival rate ranging between 30 and 40%. Due to the asymptomatic nature of the condition, it is more likely to be diagnosed at an advanced stage, requiring an aggressive therapeutic approach. Cytoreductive surgery (CRS) along with systemic chemotherapy with paclitaxel and carboplatin has been the mainstay of the treatment in the frontline management of EOC. In recent years, neo-adjuvant chemotherapy… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
9
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
2

Relationship

0
10

Authors

Journals

citations
Cited by 23 publications
(11 citation statements)
references
References 93 publications
0
9
0
Order By: Relevance
“…Patients with ovarian cancer have an insidious onset: early symptoms are not evident and are difficult to detect, and close to 80% of patients are at advanced stages when diagnosed [ 3 ]. Despite optimal surgery and chemotherapy, approximately 80% of patients with advanced ovarian cancer relapse after paclitaxel/platinum-based first-line chemotherapy, with a median progression-free survival of 12–18 months [ 3 ] and a five-year survival rate of 30–40% [ 4 ]. Therefore, it is essential to elucidate the critical mechanisms of ovarian tumourigenesis and progression to identify effective tumour diagnostic biomarkers and design new therapeutic approaches to improve prognosis.…”
Section: Introductionmentioning
confidence: 99%
“…Patients with ovarian cancer have an insidious onset: early symptoms are not evident and are difficult to detect, and close to 80% of patients are at advanced stages when diagnosed [ 3 ]. Despite optimal surgery and chemotherapy, approximately 80% of patients with advanced ovarian cancer relapse after paclitaxel/platinum-based first-line chemotherapy, with a median progression-free survival of 12–18 months [ 3 ] and a five-year survival rate of 30–40% [ 4 ]. Therefore, it is essential to elucidate the critical mechanisms of ovarian tumourigenesis and progression to identify effective tumour diagnostic biomarkers and design new therapeutic approaches to improve prognosis.…”
Section: Introductionmentioning
confidence: 99%
“…In terms of treatment, although surgical removal of the tumor combined with platinum-based paclitaxel chemotherapy remains the standard, signi cant challenges exist in improving treatment e cacy and patient survival rates. 5 A critical issue is that about 75% of patients experience recurrence after initial treatment response, eventually developing resistance to platinum drugs. This high recurrence and resistance rate highlights the limitations of current treatment approaches and emphasizes the importance of developing new strategies.…”
Section: Introductionmentioning
confidence: 99%
“…Developing effective screening strategies for asymptomatic cancer patients could decrease the incidence of late-stage cancer and increase the effectiveness of cancer treatment. However, the early detection of asymptomatic and developing cancers is challenging [ 5 , 6 ]. We are confronted with the formidable challenges of metastasis and chemoresistance, which represent crucial impediments in the landscape of cancer therapy [ 7 , 8 ].…”
Section: Introductionmentioning
confidence: 99%